Tianeptine - Revive Therapeutics

Drug Profile

Tianeptine - Revive Therapeutics

Alternative Names: REV-001; REV-003

Latest Information Update: 17 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revive Therapeutics
  • Developer Leiden University; Revive Therapeutics
  • Class Irritable bowel syndrome therapies; Small molecules; Thiazepines; Tricyclic antidepressants
  • Mechanism of Action Serotonin uptake stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rett syndrome
  • No development reported Respiratory insufficiency

Most Recent Events

  • 27 Jun 2014 Efficacy and adverse events data from the second part of a phase IIa trial in Respiratory insufficiency released by Revive Therapeutics
  • 14 May 2014 Preclinical trials in Rett syndrome in Canada (unspecified route)
  • 14 May 2014 Pharmacodynamics data from a preclinical study in Rett syndrome released by Revive Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top